Ozempic maker Novo Nordisk gets another downgrade. The end’s in sight for its duopoly status, says TD Cowen.
Up next
Author


Novo Nordisk on Tuesday received a broker downgrade, with the analysts arguing that its status as a duopoly in both diabetes and weight loss are under threat.

You May Also Like
Oil prices hold ground at 5-month highs on supply-demand risks

Oil prices hold ground at 5-month highs on supply-demand risks

Oil futures hold ground Tuesday at their highest prices since October.
Economists cheer end of ‘crippling uncertainty’ but U.S. tariff deal gets frosty reception in Europe

Economists cheer end of ‘crippling uncertainty’ but U.S. tariff deal gets frosty reception in Europe

U.S. and E.U. agree a 15% tariff deal
Fresh uncertainty around Fed rate cuts exposes the stock market’s winners and losers

Fresh uncertainty around Fed rate cuts exposes the stock market’s winners and losers

Higher U.S. inflation is dashing investors’ hopes for multiple Federal Reserve rate…
Job openings in the U.S. fall to the lowest level in 3 1/2 years

Job openings in the U.S. fall to the lowest level in 3 1/2 years

U.S. job openings fell in September to a three-and-a-half year low as…